<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109113">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01712464</url>
  </required_header>
  <id_info>
    <org_study_id>12-033</org_study_id>
    <nct_id>NCT01712464</nct_id>
  </id_info>
  <brief_title>Modulation of Reinforcement Learning</brief_title>
  <official_title>Modulation of Reinforcement Learning and Neuronal Activation in Ventral Stratum by Oxytocin - a Pilot Study at Autism Spectrum Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to examine the modulation of neuronal and behavioural parameters of social
      reinforcement learning.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Bold Signal in nucleus accumbens</measure>
    <time_frame>1 Day</time_frame>
    <safety_issue>No</safety_issue>
    <description>during social learning at one treatment with oxytocin vs placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bold signal in ventral tegmental areal</measure>
    <time_frame>1 Day</time_frame>
    <safety_issue>No</safety_issue>
    <description>during social learning at one treatment with oxytocin vs placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Impact of Oxytocin on Social Learning</condition>
  <arm_group>
    <arm_group_label>Cross over Oxytocin and Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cross over Placebo and Oxytocin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin vs. Placebo</intervention_name>
    <description>FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days</description>
    <arm_group_label>Cross over Oxytocin and Placebo</arm_group_label>
    <arm_group_label>Cross over Placebo and Oxytocin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 25 years

          -  male

          -  IQ&gt;80

          -  written informed consent

          -  proband understands character, extent and individual consequences of the study

          -  competent persons who are able to follow the instructions of the study
             personnel

          -  for ASD patients: assured ASD diagnosis, comply of the ASD criteria ADI-R/ADOS-G

        Exclusion Criteria:

          -  prosopagnosia

          -  anaphylaxis of oxytocin or other chemical substances

          -  metal inside the body or other contraindications of mri scan

          -  physical illness which can affect the examinations or endanger the proband

          -  actual or assumed drug or alcohol abuse

          -  persons who are accommodated in an institution because of court or administrative
             order

          -  persons with a relationship of dependence to the sponsor or investigator

          -  healthy probands: psychiatric disorder according to ICD-10-WHO F at the moment and in
             history, continuous drug-intake at time of measurements

          -  patients with ASD: psychiatric disorder according to ICD-10-WHO F (except ASD
             disorder in patient group) during the last 12 month being not treated, continuous
             drug-intake at time of measurements (psychotropic medication), exception: stimulants
             used for treatment of attention disorders, if they can come off for the measurements
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Schulte-Rüther, Dr. rer. nat</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Aachen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Schulte-Rühter, Dr. rer. nat.</last_name>
    <phone>+49 241 80 89892</phone>
    <email>mschulte@ukaachen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universtiy Hospital Aachen</name>
      <address>
        <city>Aachen</city>
        <state>Northrhine-Westfalia</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Schulte-Rüther, Dr. rer. nat.</last_name>
      <phone>+49 241 80 89892</phone>
      <email>mschulte@ukaachen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 21, 2013</lastchanged_date>
  <firstreceived_date>October 15, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
